NCT05375903 2026-01-14
A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
UroGen Pharma Ltd.
Phase 1 Completed
Clinical Trials
32 trialsNCT01926496 2025-03-07
Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%
LEO Pharma
Phase 4 Completed
NCT02078648 2025-02-03
Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme
Stemline Therapeutics, Inc.
Phase 1/2 Completed
NCT03180684 2023-08-25
Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)
Inovio Pharmaceuticals
Phase 2 Completed
NCT00189280 2022-02-22
Aldara for the Treatment of Large and/or Multiple sBCC
Viatris Inc.
Phase 3 Completed
NCT00189241 2022-02-07
A Study to Evaluate Effectiveness of Imiquimod 5% Cream in Superficial Basal Cell Carcinoma
Viatris Inc.
Phase 3 Completed
NCT00189254 2022-02-07
A Study to Follow up Recurrence Rates of Actinic Keratoses One Year After Completion of Study 1487-IMIQ
Viatris Inc.
Completed
NCT00189267 2022-02-07
A Study to Evaluate the Effectiveness and Safety of Multiple Applications of Imiquimod 5% Cream for the Treatment of Actinic Keratoses in Organ Transplant Recipients
Viatris Inc.
Phase 2 Completed
NCT00189293 2022-02-07
Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital Warts
Viatris Inc.
Phase 4 Completed
NCT00294320 2022-02-07
Evaluation of Two Different Non-invasive Techniques to Monitor the Clearance of Actinic Keratosis Lesions
Viatris Inc.
Phase 3 Completed
NCT00761371 2022-02-07
Imiquimod 5% Cream in the Treatment of External Genital or Perianal Warts in HIV+ Patients
Viatris Inc.
Phase 4 Completed
NCT00777127 2022-02-07
LEIDA
Viatris Inc.
Phase 4 Completed
NCT01453179 2022-02-07
LEIDA 2
Viatris Inc.
Phase 4 Completed
NCT02482428 2021-01-05
Efficacy and Tolerability of Topical LFX453 for External Genital Warts
Novartis
Phase 2 Completed
NCT01686152 2020-11-24
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
Teva Pharmaceuticals USA
Phase 3 Completed
NCT00948428 2020-09-04
Bioequivalence of Generic Imiquimod Cream, 5% When Compared to Aldaraâ„¢ (Imiquimod) Cream, 5% in the Treatment of Actinic Keratosis
Actavis Inc.
Phase 3 Completed
NCT02120898 2019-12-13
A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Participants With Actinic Keratoses
Actavis Inc.
Phase 3 Completed
NCT02362152 2019-12-13
RAPID-ACT
LEO Pharma
Completed
NCT02234921 2018-10-11
DRibble
UbiVac
Phase 1 Completed
NCT01909752 2017-07-06
Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer
UbiVac
Phase 2 Completed
NCT01731652 2015-02-10
Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer
Telormedix SA
Phase 2 Completed
NCT00828568 2014-01-28
Bioequivalence Study of Two Imiquimod Cream 5%
Sun Pharmaceutical Industries, Inc.
Phase 1 Completed
NCT01788007 2014-01-22
Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.
Sun Pharmaceutical Industries, Inc.
Phase 1 Completed
NCT01611480 2013-06-26
Efficacy and Safety of a New Topical Formulation With Imiquimod (Limtop) Applied 1, 3 or 7 Times Weekly During 2 x 2 Weeks Treatment for Actinic Keratosis on the Head
Moberg Pharma AB
Phase 2 Completed
NCT00785122 2013-05-16
IMA910-101
Immatics Biotechnologies GmbH
Phase 1/2 Completed
NCT00674739 2011-05-24
Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts
Graceway Pharmaceuticals, LLC
Phase 3 Completed
NCT00651703 2010-11-15
Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients
Cytos Biotechnology AG
Phase 2 Completed
NCT00335179 2010-07-23
Cellular and Molecular Events During Treatment of Actinic Keratosis With Imiquimod 5% Cream
Graceway Pharmaceuticals, LLC
Phase 2 Completed
NCT00129519 2010-07-16
A Study to Evaluate the Effectiveness of Imiquimod 5% Cream for Basal Cell Carcinoma Recurrence
Graceway Pharmaceuticals, LLC
Phase 3 Completed
NCT00859105 2009-03-10
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Therapeutic Equivalence Study of Three Imiquimod Cream 5% Treatments for Patients With Actinic Keratosis
Apotex Inc.
Phase 3 Completed
NCT00114023 2007-02-19
1-Year Follow up to the 1473-IMIQ Study
Graceway Pharmaceuticals, LLC
Completed
NCT00115154 2007-02-19
Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Arms and Hands
Graceway Pharmaceuticals, LLC
Phase 4 Completed